152 related articles for article (PubMed ID: 34586961)
1. Intracameral sustained release bimatoprost implants (Durysta).
Sirinek PE; Lin MM
Semin Ophthalmol; 2022 Apr; 37(3):385-390. PubMed ID: 34586961
[TBL] [Abstract][Full Text] [Related]
2. Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues.
Seal JR; Robinson MR; Burke J; Bejanian M; Coote M; Attar M
J Ocul Pharmacol Ther; 2019; 35(1):50-57. PubMed ID: 30335560
[TBL] [Abstract][Full Text] [Related]
3. Intraocular Pressure Effects and Mechanism of Action of Topical Versus Sustained-Release Bimatoprost.
Lee SS; Almazan A; Decker S; Zhong Y; Ghebremeskel AN; Hughes P; Robinson MR; Burke JA; Weinreb RN
Transl Vis Sci Technol; 2019 Jan; 8(1):15. PubMed ID: 30713809
[TBL] [Abstract][Full Text] [Related]
4. Bimatoprost sustained-release intracameral implant reduces episcleral venous pressure in dogs.
Lee SS; Burke J; Shen J; Almazan A; Orilla W; Hughes P; Zhang J; Li H; Struble C; Miller PE; Robinson MR
Vet Ophthalmol; 2018 Jul; 21(4):376-381. PubMed ID: 29457333
[TBL] [Abstract][Full Text] [Related]
5. Episcleral Venous Pressure and the Ocular Hypotensive Effects of Topical and Intracameral Prostaglandin Analogs.
Lee SS; Robinson MR; Weinreb RN
J Glaucoma; 2019 Sep; 28(9):846-857. PubMed ID: 31261285
[TBL] [Abstract][Full Text] [Related]
6. Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications.
Belamkar A; Harris A; Zukerman R; Siesky B; Oddone F; Verticchio Vercellin A; Ciulla TA
Ann Med; 2022 Dec; 54(1):343-358. PubMed ID: 35076329
[TBL] [Abstract][Full Text] [Related]
7. Dose-Response of Intracameral Bimatoprost Sustained-Release Implant and Topical Bimatoprost in Lowering Intraocular Pressure.
Lee SS; Dibas M; Almazan A; Robinson MR
J Ocul Pharmacol Ther; 2019 Apr; 35(3):138-144. PubMed ID: 30698494
[TBL] [Abstract][Full Text] [Related]
8. Effect of bimatoprost sustained-release intracameral implant on intraocular pressure and medication burden in patients with prior glaucoma surgery.
Bowers ME; Wong MK; Ventimiglia J; Nicknam RM; Moster MR; Pro MJ; Dale E; Kolomeyer NN; Lee D; Zheng CX
J Fr Ophtalmol; 2024 Feb; 47(2):103996. PubMed ID: 37926661
[TBL] [Abstract][Full Text] [Related]
9. 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients.
Craven ER; Walters T; Christie WC; Day DG; Lewis RA; Goodkin ML; Chen M; Wangsadipura V; Robinson MR; Bejanian M;
Drugs; 2020 Feb; 80(2):167-179. PubMed ID: 31884564
[TBL] [Abstract][Full Text] [Related]
10. Matrix Metalloproteinases and Glaucoma Treatment.
Weinreb RN; Robinson MR; Dibas M; Stamer WD
J Ocul Pharmacol Ther; 2020 May; 36(4):208-228. PubMed ID: 32233938
[TBL] [Abstract][Full Text] [Related]
11. Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2).
Bacharach J; Tatham A; Ferguson G; Belalcázar S; Thieme H; Goodkin ML; Chen MY; Guo Q; Liu J; Robinson MR; Bejanian M; Wirta DL;
Drugs; 2021 Nov; 81(17):2017-2033. PubMed ID: 34724172
[TBL] [Abstract][Full Text] [Related]
12. Real-World Study of the Effectiveness and Safety of Intracameral Bimatoprost Implant in a Clinical Setting in the United States.
Teymoorian S; Craven ER; Nguyen L; Werts E
Clin Ophthalmol; 2024; 18():187-199. PubMed ID: 38263954
[TBL] [Abstract][Full Text] [Related]
13. Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial.
Lewis RA; Christie WC; Day DG; Craven ER; Walters T; Bejanian M; Lee SS; Goodkin ML; Zhang J; Whitcup SM; Robinson MR;
Am J Ophthalmol; 2017 Mar; 175():137-147. PubMed ID: 28012819
[TBL] [Abstract][Full Text] [Related]
14. Bimatoprost Implant: First Approval.
Shirley M
Drugs Aging; 2020 Jun; 37(6):457-462. PubMed ID: 32447639
[TBL] [Abstract][Full Text] [Related]
15. Nonclinical Pharmacokinetic and Pharmacodynamic Assessment of Bimatoprost Following a Single Intracameral Injection of Sustained-Release Implants.
Shen J; Robinson MR; Struble C; Attar M
Transl Vis Sci Technol; 2020 Mar; 9(4):20. PubMed ID: 32818107
[TBL] [Abstract][Full Text] [Related]
16. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
Easthope SE; Perry CM
Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
[TBL] [Abstract][Full Text] [Related]
17. Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1).
Medeiros FA; Walters TR; Kolko M; Coote M; Bejanian M; Goodkin ML; Guo Q; Zhang J; Robinson MR; Weinreb RN;
Ophthalmology; 2020 Dec; 127(12):1627-1641. PubMed ID: 32544560
[TBL] [Abstract][Full Text] [Related]
18. Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study.
Rubião F; Araújo ACF; Sancio JB; Nogueira BS; Franca JR; Nogueira JC; Ferreira AJ; Faraco AAG; Foureaux G; Cronemberger S
Curr Drug Deliv; 2021; 18(7):1022-1026. PubMed ID: 33388018
[TBL] [Abstract][Full Text] [Related]
19. Single Administration of Intracameral Bimatoprost Implant 10 µg in Patients with Open-Angle Glaucoma or Ocular Hypertension.
Medeiros FA; Sheybani A; Shah MM; Rivas M; Bai Z; Werts E; Ahmed IIK; Craven ER
Ophthalmol Ther; 2022 Aug; 11(4):1517-1537. PubMed ID: 35643967
[TBL] [Abstract][Full Text] [Related]
20. Phase 3, Randomized Study Comparing Intracameral Bimatoprost Implant 15 µg and Selective Laser Trabeculectomy in Patients with Open-Angle Glaucoma or Ocular Hypertension.
Christie WC; Basha MM; Ho Q; Kim K; Craven ER; Kolko M
Clin Ophthalmol; 2023; 17():3023-3036. PubMed ID: 37850049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
